Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling

被引:165
作者
Gordon, GJ
Rockwell, GN
Jensen, RV
Rheinwald, JG
Glickman, JN
Aronson, JP
Pottorf, BJ
Nitz, MD
Richards, WG
Sugarbaker, DJ
Bueno, R
机构
[1] Harvard Univ, Div Thorac Surg, Sch Med,Thorac Surg Oncol Lab, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[5] Univ Massachusetts, Dept Phys, Boston, MA 02125 USA
关键词
D O I
10.1016/S0002-9440(10)62492-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Malignant pleural mesothelioma (MPM) is a highly lethal, poorly understood neoplasm that is typically associated with asbestos exposure. We performed transcriptional profiling using high-density oligonucleotide microarrays containing similar to 22,000 genes to elucidate potential molecular and pathobiological pathways in MPM using discarded human MPM tumor specimens (n = 40), normal lung specimens (n = 4), normal pleura specimens (n = 5), and MPM and SV40-immortalized mesothelial cell fines (n = 5). in global expression analysis using unsupervised clustering techniques, we found two potential subclasses of mesothelioma that correlated loosely with tumor histology. We also identified sets of genes with expression levels that distinguish between multiple tumor subclasses, normal and tumor tissues, and tumors with different morphologies. Microarray gene expression data were confined using quantitative reverse transcriptase-polymerase chain reaction and protein analysis for three novel candidate oncogenes (NME2, CRI1, and PDGFC) and one candidate tumor suppressor (GSN). Finally, we used bioinformatics tools (ie, software) to create and explore complex physiological pathways. Combined, all of these data may advance our understanding of mesothefioma tumorigenesis, pathobiology, or both.
引用
收藏
页码:1827 / 1840
页数:14
相关论文
共 66 条
[51]   A two-stage, p16INK4A- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status [J].
Rheinwald, JG ;
Hahn, WC ;
Ramsey, MR ;
Wu, JY ;
Guo, ZY ;
Tsao, H ;
De Luca, M ;
Catricalà, C ;
O'Toole, KM .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (14) :5157-5172
[52]   Differential gene expression in mesothelioma [J].
Rihn, BH ;
Mohr, S ;
McDowell, SA ;
Binet, S ;
Loubinoux, J ;
Galateau, F ;
Keith, G ;
Leikauf, GD .
FEBS LETTERS, 2000, 480 (2-3) :95-100
[53]   Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10 [J].
Sagawa, N ;
Fujita, H ;
Banno, Y ;
Nozawa, Y ;
Katoh, H ;
Kuzumaki, N .
BRITISH JOURNAL OF CANCER, 2003, 88 (04) :606-612
[54]   Regulation of tumor cell chemotaxis by type IV collagen is mediated by a Ca2+-dependent mechanism requiring CD47 and the integrin αvβ3 [J].
Shahan, TA ;
Fawzi, A ;
Bellon, G ;
Monboisse, JC ;
Kefalides, NA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (07) :4796-4802
[55]  
Singhal S, 2003, CLIN CANCER RES, V9, P3080
[56]   Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma - Results in 120 consecutive patients [J].
Sugarbaker, DJ ;
Garcia, JP ;
Richards, WG ;
Harpole, DH ;
HealyBaldini, E ;
DeCamp, MM ;
Mentzer, SJ ;
Liptay, MJ ;
Strauss, GM ;
Swanson, SJ .
ANNALS OF SURGERY, 1996, 224 (03) :288-294
[57]  
SUGARBAKER DJ, 1996, COMPREHENSIVE TXB TH, P786
[58]   Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas [J].
Thirkettle, I ;
Harvey, P ;
Hasleton, PS ;
Ball, RY ;
Warn, RM .
HISTOPATHOLOGY, 2000, 36 (06) :522-528
[59]   Hepatocyte growth factor scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma [J].
Tolnay, E ;
Kuhnen, C ;
Wiethege, T ;
Konig, JE ;
Voss, B ;
Muller, KM .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (06) :291-296
[60]   Genetic clinical markers of human neuroblastoma with special reference to N-myconcogene: Amplified or not amplified? - An overview [J].
Tsuchida, Y ;
Hemmi, H ;
Inoue, A ;
Obana, K ;
Yang, HW ;
Hayashi, Y ;
Kanda, N ;
Shimatake, H .
TUMOR BIOLOGY, 1996, 17 (02) :65-74